ArticleJACC. Advances2026
Stroke Risk After TAVR: Balloon-Expandable vs Self-Expanding Valves in Community Practice.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStroke is a serious complication after transcatheter aortic valve replacement (TAVR), yet contemporary data from community hospital practice are limited.
objectivesThe purpose of this study was to evaluate the association between valve type and the risk of stroke within 1 year after contemporary TAVR in community practice.
methodsWe analyzed patients who underwent TAVR across CommonSpirit Health hospitals from January 2021 to February 2023 using data from the Society of Thoracic Surgeons (STS)/American College of Cardiology Transcatheter Valve Therapy Registry. Valve type was categorized as balloon-expandable valves or self-expanding valves (SEV). The primary outcome was stroke within 1 year. Kaplan-Meier methods were used to compare stroke-free survival between valve types. Baseline differences were adjusted using inverse probability of treatment weighting. Independent predictors of stroke were identified using weighted time-to-event models.
resultsA total of 6,663 patients underwent TAVR during the study period; 5,445 (81.7%) received balloon-expandable valve, and 1,218 (18.3%) received SEV. More females received a SEV (56.7% vs 37.5%; P < 0.001). The STS risk score (4.5 ± 3.8 vs 4.0 ± 3.5; P < 0.001) was higher in the SEV group. A total of 87 (1.3%) patients experienced stroke within the study period. The primary endpoint of stroke-free survival at 1 year was not different between valve types (log-rank P = 0.448). After inverse probability of treatment weighting adjustment, valve type was not associated with stroke (adjusted HR: 1.54; 95% CI: 0.79-2.68; P = 0.294). Age, lower body mass index, prior stroke, STS risk, and alternative access were associated with stroke.
conclusionsIn this registry of patients receiving TAVR, valve type did not predict stroke at 1 year. The predominant drivers of stroke were clinical variables: age, STS risk, and a history of stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.